{"id":104840,"date":"2026-07-17T20:40:10","date_gmt":"2026-07-17T20:40:10","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/104840\/"},"modified":"2026-07-17T20:40:10","modified_gmt":"2026-07-17T20:40:10","slug":"can-novartis-fabhalta-strengthen-its-nephrology-franchise","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/104840\/","title":{"rendered":"Can Novartis&#8217; Fabhalta Strengthen Its Nephrology Franchise?"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis NVS announced that the FDA has granted traditional approval to Fabhalta (iptacopan) for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This traditional approval converts the drug&#8217;s August 2024 accelerated approval, which was based on reduction of proteinuria in primary IgAN, into a full approval after a priority review.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Fabhalta is an oral Factor B inhibitor designed to selectively target the alternative complement pathway, one of the key drivers of glomerular inflammation and kidney damage in IgAN.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The approval is supported by data from the phase III APPLAUSE-IgAN study, in which Fabhalta significantly slowed kidney function decline compared with placebo over two years. Patients treated with Fabhalta recorded an annualized decline in estimated glomerular filtration rate (eGFR) of 3.0 mL\/min\/1.73 m\u00b2 per year versus 5.7 mL\/min\/1.73 m\u00b2 per year for placebo, demonstrating a clinically meaningful benefit.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Fabhalta also showed a favorable safety profile consistent with previous studies.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The drug has received regulatory approvals in multiple complement-mediated diseases, including IgAN, and is being evaluated across a range of rare kidney conditions.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Fabhalta sales of $169 million more than doubled in the first quarter of 2026, reflecting continued expansion in paroxysmal nocturnal hemoglobinuria and renal indications.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The approval further strengthens Novartis&#8217; kidney disease portfolio. In addition to Fabhalta, the company&#8217;s renal disease portfolio includes Vanrafia (atrasentan) and investigational candidate zigakibart for IgAN, reinforcing its long-term growth strategy in nephrology.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Per NVS, Vanrafia is the first and only selective endothelin A receptor antagonist approved for primary IgAN. Vanrafia received accelerated approval in the United States and China for reduction of proteinuria in adults with IgAN in 2025.  <\/p>\n<p>        Competition for NVS in Kidney Disease Market          <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Travere Therapeutics TVTX is focused on developing and commercializing therapies for rare kidney and metabolic diseases. TVTX&#8217;s lead drug, Filspari (sparsentan), is approved in the United States to slow kidney function decline in adults with primary IgAN at risk of disease progression and to reduce proteinuria in adult and pediatric patients (aged 8 years and older) with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Travere Therapeutics continues to see strong commercial momentum for Filspari, supporting its revenue growth.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Beyond Filspari, Travere Therapeutics is advancing pegtibatinase as a potential treatment for classical homocystinuria, a rare inherited metabolic disorder that can cause serious complications affecting the eyes, skeleton, circulatory system and central nervous system.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Vertex Pharmaceuticals VRTX recently announced that the FDA has accepted its biologics license Application (BLA) for povetacicept, an investigational dual BAFF\/APRIL inhibitor for adults with immunoglobulin A nephropathy (IgAN). The FDA has assigned a target action date of Nov. 30, 2026.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">If approved, VRTX will launch the first commercial product in its emerging nephrology franchise.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The approval would strengthen Vertex Pharmaceuticals&#8217; long-term growth strategy by expanding beyond cystic fibrosis into nephrology.  <\/p>\n<p>       NVS Price, Valuation and Estimates         <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Year to date, shares of Novartis have gained 10.8% compared with the industry&#8217;s growth of 8.7%.  <\/p>\n<p>   <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/747481034422563E46E73DEE5B58E896636FD6B82C8624A9B6C51AAE145EC375\/subgraphmysterio\/resizefit_w960;quality_80;format_webp\/https:%2F%2Fmedia.zenfs.com%2Fen%2Fzacks.com%2F5ad8d51164146c0499d7702f96260fbf\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Zacks Investment Research\" height=\"282\" width=\"619\" class=\"yf-lglytj loader\"\/><\/a> Zacks Investment Research          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Image Source: Zacks Investment Research  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">From a valuation standpoint, NVS is trading at a discount to the large-cap pharma industry. Going by the price\/earnings ratio, shares currently trade at 16.447X forward earnings, higher than its mean of 13.67X but lower than the large-cap pharma industry&#8217;s 18.46X.  <\/p>\n<p>   <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/132BE15590528CAF51CF83FE982C1E01C694454D09175259973ED1C023BBDB18\/subgraphmysterio\/resizefit_w960;quality_80;format_webp\/https:%2F%2Fmedia.zenfs.com%2Fen%2Fzacks.com%2Fae1b4439de169c2efb751de7cf88b882\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Zacks Investment Research\" height=\"223\" width=\"619\" class=\"yf-lglytj loader\"\/><\/a> Zacks Investment Research          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Image Source: Zacks Investment Research  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The Zacks Consensus Estimate for 2026 EPS has moved south to $8.76 from $8.87 in the past 60 days, while that for 2027 has moved south to $9.72 from $9.83 in the same time frame.  <\/p>\n<p>   <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/6CFE36933469CCAAAB027A91F687D4154521CD852B54A1EF4AA978D0185CB3B0\/subgraphmysterio\/resizefit_w960;quality_80;format_webp\/https:%2F%2Fmedia.zenfs.com%2Fen%2Fzacks.com%2F61672e28b33865f5def0d467b5d0f554\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Zacks Investment Research\" height=\"352\" width=\"607\" class=\"yf-lglytj loader\"\/><\/a> Zacks Investment Research          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Image Source: Zacks Investment Research  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today&#8217;s Zacks #1 Rank (Strong Buy) stocks here.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href=\"https:\/\/www.zacks.com\/registration\/pfp\/?ALERT=RPT_7BEST_YHOSYND&amp;ADID=SYND_YAHOO_7BEST_ANALYSTBLOG_252_2955842&amp;cid=CS-YAHOO-FT-analyst_blog|quick_take-2955842&amp;t=NVS\" data-ylk=\"slk:Click%20to%20get%20this%20free%20report;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Click to get this free report&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Click to get this free report<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.zacks.com\/registration\/pfp?ALERT=YAHOO_ZER&amp;d_alert=ZER_CONF&amp;t=NVS&amp;ADID=SYND_YAHOO_TCK_ANALYSTBLOG_252_2955842_NVS&amp;cid=CS-YAHOO-FT-analyst_blog|quick_take-2955842\" data-ylk=\"slk:Novartis%20AG%20(NVS)%20%3A%20Free%20Stock%20Analysis%20Report;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Novartis AG (NVS) : Free Stock Analysis Report&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Novartis AG (NVS) : Free Stock Analysis Report<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.zacks.com\/registration\/pfp?ALERT=YAHOO_ZER&amp;d_alert=ZER_CONF&amp;t=VRTX&amp;ADID=SYND_YAHOO_TCK_ANALYSTBLOG_252_2955842_VRTX&amp;cid=CS-YAHOO-FT-analyst_blog|quick_take-2955842\" data-ylk=\"slk:Vertex%20Pharmaceuticals%20Incorporated%20(VRTX)%20%3A%20Free%20Stock%20Analysis%20Report;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.zacks.com\/registration\/pfp?ALERT=YAHOO_ZR&amp;d_alert=rd_final_rank&amp;t=TVTX&amp;ADID=SYND_YAHOO_TCK_ANALYSTBLOG_252_2955842_TVTX&amp;cid=CS-YAHOO-FT-analyst_blog|quick_take-2955842\" data-ylk=\"slk:Travere%20Therapeutics%2C%20Inc.%20(TVTX)%20%3A%20Free%20Stock%20Analysis%20Report;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Travere Therapeutics, Inc. (TVTX) : Free Stock Analysis Report&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Travere Therapeutics, Inc. (TVTX) : Free Stock Analysis Report<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.zacks.com\/stock\/news\/2955842\/can-novartis-fabhalta-strengthen-its-nephrology-franchise?cid=CS-YAHOO-FT-analyst_blog|quick_take-2955842&amp;t=NVS\" data-ylk=\"slk:This%20article%20originally%20published%20on%20Zacks%20Investment%20Research%20(zacks.com).;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;This article originally published on Zacks Investment Research (zacks.com).&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">This article originally published on Zacks Investment Research (zacks.com).<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.zacks.com\/?t=NVS&amp;cid=CS-YAHOO-FT-analyst_blog|quick_take-2955842\" data-ylk=\"slk:Zacks%20Investment%20Research;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Zacks Investment Research&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Zacks Investment Research<\/a>  <\/p>\n","protected":false},"excerpt":{"rendered":"Novartis NVS announced that the FDA has granted traditional approval to Fabhalta (iptacopan) for slowing kidney function decline&hellip;\n","protected":false},"author":2,"featured_media":104841,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[51370,10033,23781,4337,23705,6646,206,51482,51481,28743,472],"class_list":["post-104840","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-alternative-complement-pathway","tag-disease-progression","tag-fabhalta","tag-fda","tag-kidney-damage","tag-kidney-function","tag-novartis","tag-proteinuria","tag-travere-therapeutics","tag-vertex-pharmaceuticals","tag-zacks-investment-research"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116937255927409390","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/104840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=104840"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/104840\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/104841"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=104840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=104840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=104840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}